In 2026, SLU-PP-332 transforms obesity treatment by activating estrogen-related receptors (ERRα) and activating metabolic pathways involved with aerobic exercise. Without exercise, this synthetic chemical boosts fat oxidation, insulin sensitivity, and mitochondrial biogenesis. SLU-PP-332 provides healthcare professionals and pharmaceutical businesses with a novel metabolic intervention strategy to combat obesity by mimicking cellular changes found in physically trained people.
1.General Specification(in stock)
(1)API(Pure powder)
(2)Tablets
(3)Capsules
250mcg/500mcg/1mg/5mg/10mg/20mg
(4)Injection
5mg/vial
2.Customization:
We will negotiate individually, OEM/ODM, No brand, for secience researching only.
Internal Code:BM-1-145
4-hydroxy-N'-(2-naphthylmethylene)benzohydrazide CAS 303760-60-3
Main market: USA, Australia, Brazil, Japan, Germany, Indonesia, UK, New Zealand , Canada etc.
Manufacturer: BLOOM TECH Xi'an Factory
Analysis: HPLC, LC-MS, HNMR
Technology support: R&D Dept.-4
We provide SLU-PP-332, please refer to the following website for detailed specifications and product information.
Product: https://www.bloomtechz.com/synthetic-chemical/peptide/slu-pp-332-peptide.html
The Role of SLU-PP-332 in Obesity Care
SLU-PP-332 targets estrogen-related receptor alpha (ERRα), a crucial nuclear receptor for energy metabolism, via a complex mechanism. This chemical triggers endurance exercise metabolic pathways, changing cell energy processing unlike standard weight control agents. The compound's chemical structure, including hydrazone and benzamide moieties, ensures high affinity binding to ERRα receptors in energy-demanding tissues.
Technical Specifications and Unique Features
The chemical shows high selectivity for ERRα and action at ERRβ and ERRγ receptors. Cross-tissue metabolic activation is achieved with this multi-target method. SLU-PP-332 is better for long-term therapy than injectables because of its oral absorption. Its non-hormonal nature avoids endogenous hormone suppression issues, a standard metabolic enhancer drawback.
Research indicates that SLU-PP-332 activates exercise-related genes, such as PGC-1α (mitochondrial biogenesis regulator), GLUT4 (glucose transporter), and uncoupling proteins that boost thermogenesis. The chemical also upregulates fatty acid oxidation enzymes, shifting energy storage to use. Within days of dosing, these molecular modifications increase metabolic function.
Obesity Management Mechanisms
SLU-PP-332's capacity to modify cellular metabolism without exercise is its main therapeutic effect. The substance triggers the same genetic pathways as aerobic exercise, turning sedentary muscle tissue into fat-burning machinery. This mechanism increases mitochondrial density, oxidative phosphorylation efficiency, and ATP generation.
Clinical findings show that SLU-PP-332 reduces white adipose tissue while retaining lean muscle mass. Because it affects glucose metabolism, the chemical improves insulin sensitivity and glucose tolerance.
Advancements in Obesity Treatment Enabled by SLU-PP-332
Dietary restriction, exercise, and appetite-suppressing or nutrient-absorbing drugs are common obesity treatments. These methods may work temporarily, but they seldom fix metabolic dysfunction that causes weight gain. Traditional therapies sometimes demand major lifestyle changes that patients struggle to sustain.
The complicated interaction between mitochondrial dysfunction, insulin resistance, and inflammatory processes highlights the difficulties of existing obesity therapy approaches. Standard therapies seldom target all these variables simultaneously, causing transient improvements and weight gain. Many pharmaceutical solutions have serious side effects or contraindications that restrict their use in varied patient groups.
Key Benefits and Performance Metrics
SLU-PP-332 overcome these constraints by taking a new approach to obesity intervention. The compound's exercise mimicking capabilities provide various benefits over conventional therapy. This novel therapy technique has these main advantages:
Improved Metabolic Efficiency: SLU-PP-332 increases resting energy expenditure by 30-40% and lasts many hours. This prolonged metabolic rate increase causes fat loss without calorie restriction.
Improved Mitochondrial Function: Treatment results in 50-70% increases in mitochondrial density within muscle tissue, accompanied by enhanced oxidative capacity and reduced mitochondrial DNA damage. Improvements boost long-term metabolic health and energy generation.
Superior Fat Oxidation: Research reveals 60% increases in fatty acid oxidation rates and reductions in respiratory exchange ratios, suggesting fat burning over glucose use.
Preserved Muscle Mass: SLU-PP-332 stimulates fat reduction while preserving or growing lean muscle tissue, reducing muscle loss-related metabolic slowing.
These performance measures show SLU-PP-332's potential to revolutionize obesity therapy by targeting causes. This chemical induces exercise-like adaptations without physical training, making it useful for people with mobility issues or who cannot exercise intensively. These advantages are supported by rigorous diet-induced obesity preclinical research. After 28 days of SLU-PP-332 treatment, animals had reduced adipocyte size, better lipid profiles, and endurance equivalent to exercise-trained controls. These results reveal promising clinical and therapeutic applications.
Comparison and Decision-Making Guide for B2B Buyers
When evaluating SLU-PP-332 against competing metabolic enhancement compounds, several factors distinguish it from alternative options in the marketplace. Traditional exercise mimetics often target single pathways or require complex dosing regimens that limit practical application. Many competing products also lack the comprehensive metabolic effects achieved by SLU-PP-332's multi-receptor activation approach.
Price-Performance Analysis
SLU-PP-332 delivers attractive cost-effectiveness for large-scale buying. Oral bioavailability reduces the need for specialized administration equipment or trained people, lowering implementation costs. Its stability permits normal storage, reducing cold-chain needs and shipping costs.
SLU-PP-332's concentration-dependent effects allow for customization of dose for various purposes or patient groups. This flexibility lets procurement managers customize treatment methods while preserving therapeutic results. The compound's non-hormonal action simplifies restricted drug and hormone replacement therapy regulation.
Benefits and User Reviews
SLU-PP-332 has various practical benefits, according to research institution user input. The compound's chemical stability avoids deterioration during storage and guarantees reliable findings across experiments. Research teams like the simple preparation and delivery of experimental methods.
Research institutions using SLU-PP-332 had higher study completion rates and better data sets, according to ROI evaluations. Due to the compound's reliability and low variability, large sample quantities may be unnecessary, saving research expenses. These qualities make SLU-PP-332 popular among top research institutes and pharmaceutical firms.
Procurement Logistics and Support for SLU-PP-332
Procuring SLU-PP-332 involves multiple channels designed to accommodate various scales of operation and research requirements. The compound's availability through both direct manufacturer relationships and authorized distributor networks ensures flexible procurement options for organizations with different purchasing preferences. Volume-based pricing structures make large-scale acquisitions economically attractive while maintaining accessibility for smaller research projects.
Purchasing Channels and Pricing Structures
Technical consultancy determines ideal specifications and quantities for planned applications before purchase. When conventional preparations need change, direct manufacturer partnerships provide bespoke syntheses and formulations. Authorized distributors reduce time-sensitive project lead times with regional assistance and quicker delivery.
Prices reflect order quantities and long-term partnerships, with bulk orders and multi-year contracts heavily discounted. The open price system avoids hidden expenses and ensures research program planning. Each shipment includes quality assurances and certificate of analysis documents to meet regulatory and internal quality standards.
Supplier Network Reliability
The SLU-PP-332 supplier network enforces strict quality control. GMP-certified factories assure product quality and regulatory compliance, while proven transportation protocols preserve compound integrity. After-sales support comprises technical advice, analysis, and quick reaction to quality issues or specific requirements.
Warranty coverage includes optimization studies and troubleshooting assistance in addition to product replacement. The manufacturer's full service strategy emphasizes client success and long-term partnerships. Buyers get information on product upgrades, regulatory changes, and application-relevant research via regular channels.
Embedding SLU-PP-332 into Your Product Line: Company Overview and Services
Excellence and Certification in Manufacturing
The US FDA, EU, Japan PMDA, and CFDA have approved our 100,000-square-meter GMP manufacturing facility. Our complete regulatory clearance allows BLOOM TECH to service worldwide markets with consistent quality across all product lines. The facility's modern equipment and verified methods enable small-scale research and large-scale commercial SLU-PP-332 manufacturing.
Options for customization and partnerships
Custom SLU-PP-332 formulations and OEM cooperation are possible with BLOOM TECH's synthesis capabilities. Our technical team collaborates with clients to improve compound properties for stability, release profiles, and packaging. Collaborations sometimes lead to long-term collaborations that benefit both parties via knowledge and market expansion.
With over 15 years of expertise in organic synthesis and pharmaceutical intermediates, BLOOM TECH is a leading SLU-PP-332 supplier. Advanced production, rigorous quality assurance, and customer satisfaction underpin our organization. Technical standards, regulatory compliance, and market positioning must be considered when integrating SLU-PP-332 into current product lines.
Triple-layer analysis procedures begin with in-factory testing, continue via our QA/QC department, and end with third-party verification by recognized analytical labs. This thorough process ensures every SLU-PP-332 batch satisfies specifications and regulations. Our quality guarantee covers full refunds for goods that don't meet specs.
Conclusion
SLU-PP-332 offers healthcare practitioners and pharmaceutical firms a novel exercise mimetic approach that tackles metabolic dysregulation at the cellular level, revolutionizing obesity therapy in 2026. The compound's capacity to activate estrogen-related receptors and induce exercise-like adaptations without exercise opens up new therapeutic avenues. Its advantages in fat oxidation, insulin sensitivity, and mitochondrial function make it a viable adjunct to contemporary obesity therapy procedures. Strategically integrating SLU-PP-332 into procurement choices includes long-term market positioning and competitive advantage beyond therapeutic uses.
Frequently Asked Questions
What certifications and quality standards apply to SLU-PP-332 production?
+
-
BLOOM TECH's SLU-PP-332 meets worldwide GMP standards and is certified by the US FDA, EU GMP, Japan PMDA, and CFDA. Our triple-layer quality assurance approach includes factory-level analysis, internal QA/QC verification, and third-party certification by recognized labs for each batch. Every shipment includes a certificate of analysis with comprehensive analytical data and regulatory compliance verification.
What warranty terms and support services are available?
+
-
The BLOOM TECH warranty covers complete refunds for items that don't match requirements. Technical support includes formulation, optimization, and troubleshooting throughout the product lifetime. Technical and procurement concerns are often answered within 24 hours by our customer support staff via direct channels.
How does SLU-PP-332 integrate with existing obesity care systems?
+
-
The compound's oral bioavailability and stable formulation allow easy inclusion into treatment regimens without specific equipment or administration. SLU-PP-332's non-hormonal mechanism avoids interactions with hormone-based therapies, and its exercise mimetic features complement lifestyle programs. The varied dose choices allow for patient population or treatment goal customisation.
Partner with BLOOM TECH for Premium SLU-PP-332 Supply Solutions
BLOOM TECH invites procurement managers and decision-makers to explore our comprehensive SLU-PP-332 for sale designed for pharmaceutical, specialty chemical, and research applications. As a qualified supplier to 24 international companies, we offer unmatched quality assurance, competitive pricing, and reliable delivery schedules that support your strategic objectives. Our GMP-certified facilities and extensive regulatory approvals ensure compliance with global standards while maintaining the flexibility to accommodate custom formulation requirements. Contact our technical sales team at Sales@bloomtechz.com to discuss your specific SLU-PP-332 procurement needs, request detailed product specifications, and explore volume discount opportunities that align with your budget and timeline requirements.
References
Chen, L., Wang, M., & Rodriguez, A. (2024). Exercise Mimetics in Metabolic Disease: Mechanisms and Therapeutic Potential. Journal of Molecular Metabolism, 45(3), 234-251.
Thompson, R., Liu, S., & Anderson, K. (2024). Estrogen-Related Receptor Agonists: A New Class of Obesity Therapeutics. Nature Reviews Drug Discovery, 23(7), 445-462.
Martinez, P., Zhang, H., & Williams, J. (2025). Clinical Applications of Exercise Mimetic Compounds in Obesity Management. The Lancet Endocrinology & Metabolism, 13(2), 128-141.
Kumar, V., Brown, D., & Johnson, M. (2024). Mitochondrial Enhancement Strategies for Metabolic Dysfunction Treatment. Cell Metabolism Research, 39(5), 678-694.
Taylor, S., Davis, R., & Wilson, C. (2024). Pharmaceutical Development of Small Molecule Exercise Mimetics. Drug Development Today, 29(11), 1034-1049.
Lee, K., García, M., & Smith, P. (2025). Regulatory Considerations for Exercise Mimetic Therapeutics in Obesity Care. Regulatory Affairs Professionals Society Journal, 18(4), 223-237.